|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
| Address1 | 1201 Maryland Avenue SW |
Address2 | Suite 900 |
| City | Washington |
State | DC |
Zip Code | 20024 |
Country | USA |
3. Principal place of business (if different than line 2)
| City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 6245-12
|
||||||||
|
6. House ID# 325050000
|
||||||||
| TYPE OF REPORT | 8. Year | 2019 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
| 10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
| INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 12. Lobbying | 13. Organizations | ||||||||
| INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
| Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
|
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
|||||||||
| Signature | Digitally Signed By: Tom DiLenge |
Date | 1/21/2020 5:16:34 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code AGR
16. Specific lobbying issues
Biomass Programs (Non-Funding)
---Implementation of the Agriculture Improvement Act of 2018
Climate Change
---RFI from House Select Committee on the Climate Crisis
EPA Regulations on Biotechnology
---EPA Plant Biotech Regulatory Policy
---H.R.4373: Engineering Biology Research and Development Act
Farm Bill Energy Programs
---H.R.1158: Minibus which consists of FY 2020 Commerce-Justice-Science, Agriculture-Rural Development-FDA, Interior-Environment, Military Construction-Veterans Affairs, and Transportation-Housing and Urban Development appropriations bills
---H.R.3164/S.2522: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act
for FY 2020
---Implementation of the Agriculture Improvement Act of 2018
Foreign Agricultural Biotechnology Laws and Regulations
---Asynchronous Approvals
---China Biotechnology Regulations
---Korea Biotechnology Regulations
---International Consistency of Regulation for Gene Edited Products
Funding for Biomass Crop Assistance Program
---H.R.1158: Minibus which consists of FY 2020 Commerce-Justice-Science, Agriculture-Rural Development-FDA, Interior-Environment, Military Construction-Veterans Affairs, and Transportation-Housing and Urban Development appropriations bills
---H.R.3164/S.2522: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act
for FY 2020
Funding for the USDA
---Biotechnology and Agriculture Trade Program
---Farm Bill Programs Energy Title IX
---H.R.1158: Minibus which consists of FY 2020 Commerce-Justice-Science, Agriculture-Rural Development-FDA, Interior-Environment, Military Construction-Veterans Affairs, and Transportation-Housing and Urban Development appropriations bills
---H.R.3164/S.2522: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2020
Genetically Engineered (GE) Animals
---FDA Proposed Guidance on Gene Editing
---FDA Regulatory Approach to Animal Biotechnology
---H.R.3164/S.2522: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2020
---Provisions on GE Salmon Labeling
Genetically Engineered (GE) Plants
---EPA Regulatory Approach to Gene Editing
---FDA Proposed Guidance on Gene Editing
The United States-Mexico-Canada Agreement
---Ag-Biotech Provisions
US-China Trade Negotiations
---Ag Biotech Provisions
USDA/APHIS Agricultural Biotechnology Regulations
---USDA Part 340 Revision
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Agriculture - Dept of (USDA), U.S. Trade Representative (USTR), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), Natl Economic Council (NEC), White House Office
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Dana |
OBrien |
|
|
|
Erick |
Lutt |
|
|
|
Hayley |
Alexander |
|
|
|
Jeanne |
Haggerty |
|
|
|
Kyle |
Kunkler |
|
|
|
Matthew |
OMara |
|
|
|
Michael |
Mattoon |
|
|
|
Andrew |
Connor |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code ANI
16. Specific lobbying issues
Genetically Engineered (GE) Animals
---FDA Proposed Guidance on Gene Editing
---FDA Regulatory Approach to Animal Biotechnology
---H.R.3164/S.2522: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2020
---Provisions on GE Salmon Labeling
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Food & Drug Administration (FDA), Agriculture - Dept of (USDA), Natl Economic Council (NEC), White House Office
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Jeanne |
Haggerty |
|
|
|
Kyle |
Kunkler |
|
|
|
Dana |
O'Brien |
|
|
|
Michael |
Mattoon |
|
|
|
Hayley |
Alexander |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
Farm Bill Energy Programs
---H.R.1158: Minibus which consists of FY 2020 Commerce-Justice-Science, Agriculture-Rural Development-FDA, Interior-Environment, Military Construction-Veterans Affairs, and Transportation-Housing and Urban Development appropriations bills
---H.R.3164/S.2522: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act
for FY 2020
Funding for Antimicrobial Resistance Programs
---H.R.2740: Consolidated Appropriations Act of 2019 (which consists of the FY 2020 Labor-Health and Human Services-Education, Defense, State-Foreign Operations, and Energy-Water Development Appropriations Bills)
---Labor, Health and Human Services, Education, and Related Agencies Appropriations Act for FY 2020 (Discussion Draft Senate)
Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
---H.R.2740: Consolidated Appropriations Act of 2019 (which consists of the FY 2020 Labor-Health and Human Services-Education, Defense, State-Foreign Operations, and Energy-Water Development Appropriations Bills)
Funding for Biofuels
---H.R.1158: Minibus which consists of FY 2020 Commerce-Justice-Science, Agriculture-Rural Development-FDA, Interior-Environment, Military Construction-Veterans Affairs, and Transportation-Housing and Urban Development appropriations bills
---H.R.1865: Minibus which consists of the Fiscal Year 2020 Labor-Health and Human Services, Education, Defense, State-Foreign Operations, and Energy and Water Development appropriations bills
---H.R.2960/S.2470: Energy and Water Development and Related Agencies Appropriations Act for FY 2020
---H.R.3052/S.2580: Department of the Interior, Environment and Related Agencies Appropriations Act for FY 2020
---H.R.3163/S.2520: Transportation, and Housing and Urban Development, and Related Agencies Appropriations Act for FY 2020
---H.R.3164/S.2522: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2020
Funding for Biomass Crop Assistance Program
---H.R.1158: Minibus which consists of FY 2020 Commerce-Justice-Science, Agriculture-Rural Development-FDA, Interior-Environment, Military Construction-Veterans Affairs, and Transportation-Housing and Urban Development appropriations bills
---H.R.3164/S.2522: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2020
Funding for Biorefineries
---H.R.1158: Minibus which consists of FY 2020 Commerce-Justice-Science, Agriculture-Rural Development-FDA, Interior-Environment, Military Construction-Veterans Affairs, and Transportation-Housing and Urban Development appropriations bills
---H.R.1865: Minibus which consists of the Fiscal Year 2020 Labor-Health and Human Services, Education, Defense, State-Foreign Operations, and Energy and Water Development appropriations bills
---H.R.2960: Energy and Water Development and Related Agencies Appropriations Act for FY 2020
---H.R.3164/S.2522: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2020
Funding for FDA
---H.R.1158: Minibus which consists of FY 2020 Commerce-Justice-Science, Agriculture-Rural Development-FDA, Interior-Environment, Military Construction-Veterans Affairs, and Transportation-Housing and Urban Development appropriations bills
---H.R.3164/S.2522: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2020
------Aderholt Full Committee Amendment on Germline Editing
Funding for Health Resources and Services Administration (HRSA)
---H.R.1865: Minibus which consists of the Fiscal Year 2020 Labor-Health and Human Services, Education, Defense, State-Foreign Operations, and Energy and Water Development appropriations bills
---Vaccine Injury Compensation Program (VICP)
Funding for National Institutes of Health
---H.R.2740: Labor, Health and Human Services, Education, and Related Agencies Appropriations Act for FY 2020
---Labor, Health and Human Services, Education, and Related Agencies Appropriations Act for FY 2020 (Discussion Draft Senate)
Funding for Renewable Chemicals/Bio-based Products
---H.R.2960/S.2470: Energy and Water Development and Related Agencies Appropriations Act for FY 2020
---H.R.3164/S.2522: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2020
Funding for the Centers for Disease Control and Prevention Vaccine Programs
---H.R.2740: Consolidated Appropriations Act of 2019 (which consists of the FY 2020 Labor-Health and Human Services-Education, Defense, State-Foreign Operations, and Energy-Water Development Appropriations Bills)
Funding for the USDA
---Biotechnology and Agriculture Trade Program
---Farm Bill Programs Energy Title IX
---H.R.1158: Minibus which consists of FY 2020 Commerce-Justice-Science, Agriculture-Rural Development-FDA, Interior-Environment, Military Construction-Veterans Affairs, and Transportation-Housing and Urban Development appropriations bills
---H.R.3164/S.2522: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2020
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Erick |
Lutt |
|
|
|
Hayley |
Alexander |
|
|
|
Jeanne |
Haggerty |
|
|
|
Kyle |
Kunkler |
|
|
|
Michael |
Mattoon |
|
|
|
Shea |
Hartley |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CHM
16. Specific lobbying issues
Climate Change
---RFI from House Select Committee on the Climate Crisis
Farm Bill Energy Programs
---H.R.1158: Minibus which consists of FY 2020 Commerce-Justice-Science, Agriculture-Rural Development-FDA, Interior-Environment, Military Construction-Veterans Affairs, and Transportation-Housing and Urban Development appropriations bills
---H.R.3164/S.2522: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act
for FY 2020
---Implementation of the Agriculture Improvement Act of 2018
Funding for Renewable Chemicals/Bio-based Products
---H.R.2960/S.2470: Energy and Water Development and Related Agencies Appropriations Act for FY 2020
---H.R.3164/S.2522: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2020
Renewable Chemicals/Bio-based Products (Non-Funding)
---H.R.2051/S.999: Sustainable Chemistry Research and Development Act of 2019
---H.R.3249/S.1841: Financing Our Energy Future Act of 2019
---Implementation of the Agriculture Improvement Act of 2018
---Investment Tax Credit
---Production Tax Credit
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Erick |
Lutt |
|
|
|
Jeanne |
Haggerty |
|
|
|
Kyle |
Kunkler |
|
|
|
Charles |
Fritts |
|
|
|
Shea |
Hartley |
|
|
|
Michael |
Mattoon |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CPT
16. Specific lobbying issues
Bayh-Dole Act/Tech Transfer
---Domestic Manufacturing Requirement
---March-In Rights
Compulsory Licensing
---H.R.465/S.102: Prescription Drug Price Relief Act of 2019
---H.R.1046/S.377: Medicare Negotiation and Competitive Licensing Act of 2019
Drug Patenting
---H.R.19/S.3129: Lower Costs, More Cures Act of 2019
---H.R.1046/S.377: Medicare Negotiation and Competitive Licensing Act of 2019
---H.R.1188/S.366: Forcing Limits on Abusive and Tumultuous (FLAT) Prices Act
---H.R.1499: Protecting Consumer Access to Generic Drugs Act of 2019
---H.R.1503: Orange Book Transparency Act of 2019
---H.R.1520: Purple Book Continuity Act of 2019
---H.R.1865: Minibus which consists of the Fiscal Year 2020 Labor-Health and Human Services, Education, Defense, State-Foreign Operations, and Energy and Water Development appropriations bills
---H.R.3199 Terminating the Extension of Rights Misappropriated (TERM) Act of 2019
---H.R.3991 Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act of 2019
---H.R.4398/S.1416: Affordable Prescriptions for Patients Act of 2019
---S.64: Preserve Access to Affordable Generics and Biosimilars Act of 2019
---S.659: Biologic Patent Transparency Act of 2019
---S.1416: Affordable Prescriptions for Patients Act of 2019
---S.1617: Second Look at Drug Patents Act of 2019
---S.1895: Lower Health Care Costs for Patients Act of 2019
Intellectual Property International Enforcement
---China
---Colombia
---India
---Malaysia
---Saudi Arabia
Inter Partes Review
---H.R.3666/S.2082: Support Technology and Research for Our Nation's Growth and Economic Resilience (STRONGER) Patents Act of 2019
---S.440: Preserving Access to Cost Effective Drugs Act (PACED) Act of 2019
Patent Reform
---H.R.3666/S.2082: Support Technology and Research for Our Nation's Growth and Economic Resilience (STRONGER) Patents Act of 2019
Patenting of Biological Inventions
---Argentina Biotech Patentability Guidelines
---DNA Patenting and Licensing
---PTO Examination Guidelines
---Section 101 Modernization
The United States-Mexico-Canada Agreement
---IP Provisions
US-China Trade Negotiations
---IP Provisions
US-Japan Trade Agreement
---IP Provisions
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, U.S. Trade Representative (USTR), Patent & Trademark Office (PTO), White House Office
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Charles |
Fritts |
|
|
|
David |
Lachmann |
|
|
|
Hans |
Sauer |
|
|
|
Jeanne |
Haggerty |
|
|
|
Matthew |
OMara |
|
|
|
Michael |
Mattoon |
|
|
|
Aiken |
Hackett |
|
|
|
Jamie |
Gregorian |
|
|
|
Claire |
Brandewie |
|
|
|
Thomas |
Brunet |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CSP
16. Specific lobbying issues
Drug Importation
---General
---H.R.1046/S.377: Medicare Negotiation and Competitive Licensing Act of 2019
---H.R.3164/S.2522: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2020
---S.97: Affordable and Safe Prescription Drug Importation Act of 2019
---S.771: Improving Access to Affordable Prescription Drugs Act of 2019
---S.844: Short on Competition Act of 2019
Genetically Engineered (GE) Animals
---FDA Proposed Guidance on Gene Editing
---FDA Regulatory Approach to Animal Biotechnology
---H.R.3164/S.2522: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2020
---Provisions on GE Salmon Labeling
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Food & Drug Administration (FDA), Agriculture - Dept of (USDA), Natl Economic Council (NEC), White House Office
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Hayley |
Alexander |
|
|
|
Jeanne |
Haggerty |
|
|
|
Kyle |
Kunkler |
|
|
|
Shea |
Hartley |
|
|
|
Michael |
Mattoon |
|
|
|
Thomas |
Brunet |
|
|
|
Dana |
O'Brien |
|
|
|
Claire |
Brandewie |
|
|
|
Aiken |
Hackett |
|
|
|
Jamie |
Gregorian |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code ENG
16. Specific lobbying issues
Biofuels (Non-Funding)
---Advanced and Second Generation Biofuels Tax Extenders
---H.R.3006: Renewable Fuel Standard Integrity Act of 2019
---H.R.3249/S.1841: Financing Our Energy Future Act of 2019
---H.R.3301: The Taxpayer Certainty and Disaster Tax Relief Act of 2019
---Implementation of the Agriculture Improvement Act of 2018
---S.1840: A bill to establish certain requirements for the small refineries exemption of the renewable fuels provisions under the Clean Air Act, and for other purposes.
Biomass Programs (Non-Funding)
---Implementation of the Agriculture Improvement Act of 2018
Biorefineries (Non-Funding)
---Implementation of the Agriculture Improvement Act of 2018
Climate Change
---RFI from House Select Committee on the Climate Crisis
Farm Bill Energy Programs
---H.R.1158: Minibus which consists of FY 2020 Commerce-Justice-Science, Agriculture-Rural Development-FDA, Interior-Environment, Military Construction-Veterans Affairs, and Transportation-Housing and Urban Development appropriations bills
---H.R.3164/S.2522: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act
for FY 2020
---Implementation of the Agriculture Improvement Act of 2018
Funding for Biofuels
---H.R.1158: Minibus which consists of FY 2020 Commerce-Justice-Science, Agriculture-Rural Development-FDA, Interior-Environment, Military Construction-Veterans Affairs, and Transportation-Housing and Urban Development appropriations bills
---H.R.1865: Minibus which consists of the Fiscal Year 2020 Labor-Health and Human Services, Education, Defense, State-Foreign Operations, and Energy and Water Development appropriations bills
---H.R.2960/S.2470: Energy and Water Development and Related Agencies Appropriations Act for FY 2020
---H.R.3052/S.2580: Department of the Interior, Environment and Related Agencies Appropriations Act for FY 2020
---H.R.3163/S.2520: Transportation, and Housing and Urban Development, and Related Agencies Appropriations Act for FY 2020
---H.R.3164/S.2522: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2020
Funding for Biomass Crop Assistance Program
---H.R.1158: Minibus which consists of FY 2020 Commerce-Justice-Science, Agriculture-Rural Development-FDA, Interior-Environment, Military Construction-Veterans Affairs, and Transportation-Housing and Urban Development appropriations bills
---H.R.3164/S.2522: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2020
Funding for Biorefineries
---H.R.1158: Minibus which consists of FY 2020 Commerce-Justice-Science, Agriculture-Rural Development-FDA, Interior-Environment, Military Construction-Veterans Affairs, and Transportation-Housing and Urban Development appropriations bills
---H.R.1865: Minibus which consists of the Fiscal Year 2020 Labor-Health and Human Services, Education, Defense, State-Foreign Operations, and Energy and Water Development appropriations bills
---H.R.2960: Energy and Water Development and Related Agencies Appropriations Act for FY 2020
---H.R.3164/S.2522: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2020
Renewable Fuel Standard (RFS)
---Cellulosic Registration Applications for Corn Kernel Fiber
---E 15 EPA Implementation of RVP Waiver
---H.R.3006: Renewable Fuel Standard Integrity Act of 2019
---RFS Reform
---S.1840: A bill to establish certain requirements for the small refineries exemption of the renewable fuels provisions under the Clean Air Act, and for other purposes.
---Small Refinery Waivers
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, White House Office
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Charles |
Fritts |
|
|
|
Erick |
Lutt |
|
|
|
Hayley |
Alexander |
|
|
|
Jeanne |
Haggerty |
|
|
|
Kyle |
Kunkler |
|
|
|
Michael |
Mattoon |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code FOO
16. Specific lobbying issues
Genetically Engineered (GE) Animals
---Amendment on GE Salmon Labeling
---FDA Proposed Guidance on Gene Editing
---FDA Regulatory Approach to Animal Biotechnology
---H.R.3164/S.2522: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2020
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Agriculture - Dept of (USDA), Food & Drug Administration (FDA), White House Office, Natl Economic Council (NEC)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Jeanne |
Haggerty |
|
|
|
Kyle |
Kunkler |
|
|
|
Dana |
O'Brien |
|
|
|
Michael |
Mattoon |
|
|
|
Hayley |
Alexander |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code FUE
16. Specific lobbying issues
Biofuels (Non-Funding)
---Advanced and Second Generation Biofuels Tax Extenders
---H.R.3006: Renewable Fuel Standard Integrity Act of 2019
---H.R.3249/S.1841: Financing Our Energy Future Act of 2019
---H.R.3301: The Taxpayer Certainty and Disaster Tax Relief Act of 2019
---Implementation of the Agriculture Improvement Act of 2018
---S.1840: A bill to establish certain requirements for the small refineries exemption of the renewable fuels provisions under the Clean Air Act, and for other purposes.
Biomass Programs (Non-Funding)
---Implementation of the Agriculture Improvement Act of 2018
Biorefineries (Non-Funding)
---Implementation of the Agriculture Improvement Act of 2018
Climate Change
---RFI from House Select Committee on the Climate Crisis
Farm Bill Energy Programs
---H.R.1158: Minibus which consists of FY 2020 Commerce-Justice-Science, Agriculture-Rural Development-FDA, Interior-Environment, Military Construction-Veterans Affairs, and Transportation-Housing and Urban Development appropriations bills
---H.R.3164/S.2522: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act
for FY 2020
---Implementation of the Agriculture Improvement Act of 2018
Funding for Biofuels
---H.R.1158: Minibus which consists of FY 2020 Commerce-Justice-Science, Agriculture-Rural Development-FDA, Interior-Environment, Military Construction-Veterans Affairs, and Transportation-Housing and Urban Development appropriations bills
---H.R.1865: Minibus which consists of the Fiscal Year 2020 Labor-Health and Human Services, Education, Defense, State-Foreign Operations, and Energy and Water Development appropriations bills
---H.R.2960/S.2470: Energy and Water Development and Related Agencies Appropriations Act for FY 2020
---H.R.3052/S.2580: Department of the Interior, Environment and Related Agencies Appropriations Act for FY 2020
---H.R.3163/S.2520: Transportation, and Housing and Urban Development, and Related Agencies Appropriations Act for FY 2020
---H.R.3164/S.2522: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2020
Funding for Biomass Crop Assistance Program
---H.R.1158: Minibus which consists of FY 2020 Commerce-Justice-Science, Agriculture-Rural Development-FDA, Interior-Environment, Military Construction-Veterans Affairs, and Transportation-Housing and Urban Development appropriations bills
---H.R.3164/S.2522: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2020
Funding for Biorefineries
---H.R.1158: Minibus which consists of FY 2020 Commerce-Justice-Science, Agriculture-Rural Development-FDA, Interior-Environment, Military Construction-Veterans Affairs, and Transportation-Housing and Urban Development appropriations bills
---H.R.1865: Minibus which consists of the Fiscal Year 2020 Labor-Health and Human Services, Education, Defense, State-Foreign Operations, and Energy and Water Development appropriations bills
---H.R.2960: Energy and Water Development and Related Agencies Appropriations Act for FY 2020
---H.R.3164/S.2522: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2020
Renewable Fuel Standard (RFS)
---Cellulosic Registration Applications for Corn Kernel Fiber
---E 15 EPA Implementation of RVP Waiver
---H.R.3006: Renewable Fuel Standard Integrity Act of 2019
---RFS Reform
---S.1840: A bill to establish certain requirements for the small refineries exemption of the renewable fuels provisions under the Clean Air Act, and for other purposes.
---Small Refinery Waivers
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, White House Office
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Charles |
Fritts |
|
|
|
Erick |
Lutt |
|
|
|
Hayley |
Alexander |
|
|
|
Jeanne |
Haggerty |
|
|
|
Kyle |
Kunkler |
|
|
|
Michael |
Mattoon |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
340B Drug Discount Program
---H.R.2740: Consolidated Appropriations Act of 2019 (which consists of the FY 2020 Labor-Health and Human Services-Education, Defense, State-Foreign Operations, and Energy-Water Development Appropriations Bills)
---Labor, Health and Human Services, Education, and Related Agencies Appropriations Act for FY 2020 (Discussion Draft Senate)
Antibiotic & Diagnostic Tax Credit
Biodefense Research, Development and Procurement Issues (Non-funding)
---Executive Order on Modernizing Influenza Vaccines
---Gene Editing
---H.R.269/S.1379: Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019
---Implementation of Medical Countermeasures Innovation Act
---Implementation of the 21st Century Cures Act of 2016
---Implementation of the Pandemic and All-Hazards Preparedness and Advancing Innovation Act (PAHPAI) of 2019
---National Biodefense Strategy
---Pandemic Influenza Preparedness
---Tropical Disease Priority Review Voucher (PRV) Program
Biosimilars
---Access to Samples for Testing
---Biosimilar Copay Elimination
---Brazil Biologics Regulations
---Canada Biologics Regulations
---Coding
---H.R.965/S.340: CREATES Act of 2019
---H.R.1499: Protecting Consumer Access to Generic Drugs Act of 2019
---H.R.1520: Purple Book Continuity Act of 2019
---Implementation and Reauthorization of the Biosimilar User Fee Act of 2017
---India Biologics Regulations
---Interchangeability and Pharmacy Substitution
---Mexico Biologics Regulations
---Naming
---Reimbursement
---S.64: Preserve Access to Affordable Generics and Biosimilars Act of 2019
---S.659: Biologic Patent Transparency Act of 2019
Climate Change
---RFI from House Select Committee on the Climate Crisis
Comparative Effectiveness Research Initiatives
---Reauthorization of Patient-Centered Outcomes Research Institute
21st Century Cures Act 2.0
---RFI from House Energy and Commerce Committee
Diagnostics and Personalized Medicine Regulation and Oversight
---VALID Act (Discussion Draft House)
Drug Evaluation and Review
---Compassionate Use/Expanded Access
---Expedited Pathways
---FDA Hiring Flexibility
---FDA Management and Financial Accountability
---FDA Review of CBD-Based Drugs
---Implementation of the Prescription Drug User Fee Act (PDUFA) VI
---Innovation Incentives
---Patient-Focused Drug Development
---Priority Review Voucher Programs
---Regulatory Reform & Modernization
---S.660: Efficiency and Transparency in Petitions Act
---Use of Real-World Evidence
Drug Importation
---General
---H.R.1046/S.377: Medicare Negotiation and Competitive Licensing Act of 2019
---H.R.3164/S.2522: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2020
---S.97: Affordable and Safe Prescription Drug Importation Act of 2019
---S.771: Improving Access to Affordable Prescription Drugs Act of 2019
---S.844: Short on Competition Act of 2019
---S.Con.Res25: The FY 2018 Budget Resolution
Drug Patenting
---H.R.19/S.3129: Lower Costs, More Cures Act of 2019
---H.R.1046/S.377: Medicare Negotiation and Competitive Licensing Act of 2019
---H.R.1188/S.366: Forcing Limits on Abusive and Tumultuous (FLAT) Prices Act
---H.R.1499: Protecting Consumer Access to Generic Drugs Act of 2019
---H.R.1503: Orange Book Transparency Act of 2019
---H.R.1520: Purple Book Continuity Act of 2019
---H.R.1865: Minibus which consists of the Fiscal Year 2020 Labor-Health and Human Services, Education, Defense, State-Foreign Operations, and Energy and Water Development appropriations bills
---H.R.3199 Terminating the Extension of Rights Misappropriated (TERM) Act of 2019
---H.R.3991 Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act of 2019
---H.R.4398/S.1416: Affordable Prescriptions for Patients Act of 2019
---S.64: Preserve Access to Affordable Generics and Biosimilars Act of 2019
---S.659: Biologic Patent Transparency Act of 2019
---S.1416: Affordable Prescriptions for Patients Act of 2019
---S.1617: Second Look at Drug Patents Act of 2019
---S.1895: Lower Health Care Costs for Patients Act of 2019
Drug Pricing
---CMMI Authority
---General
---H.R.3: Lower Drug Costs Now Act of 2019
---H.R.19/S.3129: Lower Costs, More Cures Act of 2019
---H.R.275: Medicare Prescription Drug Price Negotiation Act of 2019
---H.R.488/S.99: Medicare Drug Price Negotiation Act of 2019
---H.R.965/S.340: CREATES Act of 2019
---H.R.1046/S.377: Medicare Negotiation and Competitive Licensing Act of 2019
---H.R.1093/S.378: Stop Price Gouging Act of 2019
---H.R.1188/S.366: Forcing Limits on Abusive and Tumultuous Prices (FLAT) Prices Act of 2019
---H.R.1499: Protecting Consumer Access to Generic Drugs Act of 2019
---H.R.1503: Orange Book Transparency Act of 2019
---H.R.1520: Purple Book Continuity Act of 2019
---H.R.1865: Minibus which consists of the Fiscal Year 2020 Labor-Health and Human Services, Education, Defense, State-Foreign Operations, and Energy and Water Development appropriations bills
---H.R.2069/S.474: Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act of 2019
---H.R.2113: Prescription Drug STAR Act of 2019
---H.R.2376/S.1227: Prescription Pricing for the People Act of 2019
---H.R.2387: STOP GAMES Act of 2019
---H.R.3199 Terminating the Extension of Rights Misappropriated (TERM) Act of 2019
---H.R.3991 Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act of 2019
---H.R.4398/S.1416: Affordable Prescriptions for Patients Act of 2019
---HHS Blueprint to lower drug prices and reduce out of pocket costs
---International Pricing Index Proposal
---Labor, Health and Human Services, Education, and Related Agencies Appropriations Act for FY 2020 (Discussion Draft Senate)
---Pricing Transparency
---S.62: Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019
---S.64: Preserve Access to Affordable Generics and Biosimilars Act of 2019
---S.97: Affordable and Safe Prescription Drug Importation Act of 2019
---S.476: Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2019
---S.771: Improving Access to Affordable Prescription Drugs Act of 2019
---S.844: Short on Competition Act of 2019
---S.1416: Affordable Prescriptions for Patients Act of 2019
---S.1617: Second Look at Drug Patents Act of 2019
---S.1895: Lower Health Care Costs for Patients Act of 2019
---S.2543: Prescription Drug Pricing Reduction Act of 2019
---S.2911:Seniors Prescription Drug Relief Act of 2019
Funding for Antimicrobial Resistance Programs
---H.R.2740: Consolidated Appropriations Act of 2019 (which consists of the FY 2020 Labor-Health and Human Services-Education, Defense, State-Foreign Operations, and Energy-Water Development Appropriations Bills)
---Labor, Health and Human Services, Education, and Related Agencies Appropriations Act for FY 2020 (Discussion Draft Senate)
Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
---H.R.2740: Consolidated Appropriations Act of 2019 (which consists of the FY 2020 Labor-Health and Human Services-Education, Defense, State-Foreign Operations, and Energy-Water Development Appropriations Bills)
Funding for FDA
---Aderholt Full Committee Amendment on Germline Editing
---Biotechnology and Agriculture Trade Program
---H.R.1158: Minibus which consists of FY 2020 Commerce-Justice-Science, Agriculture-Rural Development-FDA, Interior-Environment, Military Construction-Veterans Affairs, and Transportation-Housing and Urban Development appropriations bills
---H.R.3164/S.2522: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2020
Funding for Health Resources and Services Administration (HRSA)
---H.R.1865: Minibus which consists of the Fiscal Year 2020 Labor-Health and Human Services, Education, Defense, State-Foreign Operations, and Energy and Water Development appropriations bills
---Vaccine Injury Compensation Program (VICP)
Funding for National Institutes of Health
---H.R.1865: Minibus which consists of the Fiscal Year 2020 Labor-Health and Human Services, Education, Defense, State-Foreign Operations, and Energy and Water Development appropriations bills
---Labor, Health and Human Services, Education, and Related Agencies Appropriations Act for FY 2020 (Discussion Draft Senate)
Funding for the Centers for Disease Control and Prevention Vaccine Programs
---H.R.1865: Minibus which consists of the Fiscal Year 2020 Labor-Health and Human Services, Education, Defense, State-Foreign Operations, and Energy and Water Development appropriations bills
Generic Drug Entry
---Access to Samples for Testing
---Generic Drug Application Review Reforms
---H.R.297: Increasing Competition in Pharmaceuticals Act of 2019
---H.R.749: Lower Drug Costs Through Competition Act of 2018
---H.R.938: Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019
---H.R.965/S.340: CREATES Act of 2019
---H.R.1499: Protecting Consumer Access to Generic Drugs Act of 2019
---H.R.2374/S.1224: Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (STALLING) Act of 2019
---Incentives for Generic Drug Entry
---S.64: Preserve Access to Affordable Generics and Biosimilars Act of 2019
---S.660: Efficiency and Transparency in Petitions Act
International Biosecurity Policies
Medicaid
---Alternative payment arrangements for gene therapies
---Average Manufacturer Price Calculations
---Drug Benefit Design
---Pricing and Rebates
---S.2543: Prescription Drug Pricing Reduction Act of 2019
---S.3013: Encouraging Innovative Benefit Design to Lower Costs for Seniors Act
Orphan Drug Issues
---Tax Credit
Reimbursement and Coverage of Innovative Products
---Administration Rebate Rule
---CMMI Authority
---H.R.3: Lower Drug Costs Now Act of 2019
---H.R.19/S.3129: Lower Costs, More Cures Act of 2019
---H.R.488/S.99: Medicare Drug Price Negotiation Act of 2019
---International Pricing Index Proposal
---Medicare Part B Physician-Administered Products
---Medicare Part D Prescription Drug Program
---S.2543: Prescription Drug Pricing Reduction Act of 2019
---Step Therapy
---Value-based Contracting and Communications
The United States-Mexico-Canada Agreement
---IP Provisions
US-China Trade Negotiations
---IP Provisions
US-Japan Trade Agreement
---IP Provisions
Vaccines and Infectious Diseases
---Executive Order on Modernizing Influenza Vaccines
---H.R.1973/S.1654: Vaccine Access Improvement Act of 2019
---S.1872: Protecting Seniors through Immunizations Act of 2019
---Vaccine and Anti-Microbial Resistance Product Development and Incentives
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), White House Office, U.S. Trade Representative (USTR), Health & Human Services - Dept of (HHS), Patent & Trademark Office (PTO), State - Dept of (DOS), Council of Economic Advisers (CEA), Food & Drug Administration (FDA), Office of Management & Budget (OMB)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Charles |
Fritts |
|
|
|
David |
Lachmann |
|
|
|
Hayley |
Alexander |
|
|
|
Jamie |
Gregorian |
|
|
|
Jeanne |
Haggerty |
|
|
|
Matt |
O'Mara |
|
|
|
Aiken |
Hackett |
|
|
|
Hans |
Sauer |
|
|
|
Shea |
Hartley |
|
|
|
Michael |
Mattoon |
|
|
|
Thomas |
Brunet |
|
|
|
Kyle |
Kunkler |
|
|
|
Claire |
Brandewie |
|
|
|
Cartier |
Esham |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HOM
16. Specific lobbying issues
Biodefense Research, Development and Procurement Issues (Non-funding)
---Executive Order on Modernizing Influenza Vaccines
---Gene Editing
---H.R.269/S.1379: Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019
---Implementation of Medical Countermeasures Innovation Act
---Implementation of the 21st Century Cures Act of 2016
---Implementation of the Pandemic and All-Hazards Preparedness and Advancing Innovation Act (PAHPAI) of 2019
---National Biodefense Strategy
---Pandemic Influenza Preparedness
---Tropical Disease Priority Review Voucher (PRV) Program
Funding for Antimicrobial Resistance Programs
---H.R.2740: Consolidated Appropriations Act of 2019 (which consists of the FY 2020 Labor-Health and Human Services-Education, Defense, State-Foreign Operations, and Energy-Water Development Appropriations Bills)
---Labor, Health and Human Services, Education, and Related Agencies Appropriations Act for FY 2020 (Discussion Draft Senate)
Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
---H.R.2740: Consolidated Appropriations Act of 2019 (which consists of the FY 2020 Labor-Health and Human Services-Education, Defense, State-Foreign Operations, and Energy-Water Development Appropriations Bills)
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Hayley |
Alexander |
|
|
|
Jeanne |
Haggerty |
|
|
|
Michael |
Mattoon |
|
|
|
Jamie |
Gregorian |
|
|
|
Claire |
Brandewie |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MED
16. Specific lobbying issues
Biodefense Research, Development and Procurement Issues (Non-funding)
---Executive Order on Modernizing Influenza Vaccines
---Gene Editing
---H.R.269/S.1379: Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019
---Implementation of Medical Countermeasures Innovation Act
---Implementation of the 21st Century Cures Act of 2016
---Implementation of the Pandemic and All-Hazards Preparedness and Advancing Innovation Act (PAHPAI) of 2019
---National Biodefense Strategy
---Pandemic Influenza Preparedness
---Tropical Disease Priority Review Voucher (PRV) Program
Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
---H.R.2740: Consolidated Appropriations Act of 2019 (which consists of the FY 2020 Labor-Health and Human Services-Education, Defense, State-Foreign Operations, and Energy-Water Development Appropriations Bills)
Funding for the Centers for Disease Control and Prevention Vaccine Programs
---H.R.2740: Consolidated Appropriations Act of 2019 (which consists of the FY 2020 Labor-Health and Human Services-Education, Defense, State-Foreign Operations, and Energy-Water Development Appropriations Bills)
Funding for National Institutes of Health
---H.R.2740: Consolidated Appropriations Act of 2019 (which consists of the FY 2020 Labor-Health and Human Services-Education, Defense, State-Foreign Operations, and Energy-Water Development Appropriations Bills)
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Hayley |
Alexander |
|
|
|
Jeanne |
Haggerty |
|
|
|
Michael |
Mattoon |
|
|
|
Jamie |
Gregorian |
|
|
|
Claire |
Brandewie |
|
|
|
Aiken |
Hackett |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
340B Drug Discount Program
---H.R.2740: Consolidated Appropriations Act of 2019 (which consists of the FY 2020 Labor-Health and Human Services-Education, Defense, State-Foreign Operations, and Energy-Water Development Appropriations Bills)
Biosimilars
---Biosimilar Copay Elimination
---Coding
---Reimbursement
21st Century Cures Act 2.0
---RFI from House Energy and Commerce Committee
Drug Pricing
---CMMI Authority
---H.R.3: Lower Drug Costs Now Act of 2019
---H.R.19/S.3129: Lower Costs, More Cures Act of 2019
---H.R.275: Medicare Prescription Drug Price Negotiation Act of 2019
---H.R.488/S.99: Medicare Drug Price Negotiation Act of 2019
---H.R.1046/S.377: Medicare Negotiation and Competitive Licensing Act of 2019
---H.R.1093/S.378: Stop Price Gouging Act of 2019
---H.R.2376/S.1227: Prescription Pricing for the People Act of 2019
---H.R.4398/S.1416: Affordable Prescriptions for Patients Act of 2019
---HHS Blueprint to lower drug prices and reduce out of pocket costs
---S.62: Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019
---S.64: Preserve Access to Affordable Generics and Biosimilars Act of 2019
---S.771: Improving Access to Affordable Prescription Drugs Act of 2019
---S.1416: Affordable Prescriptions for Patients Act of 2019
---S.1895: Lower Health Care Costs for Patients Act of 2019
---S.2911:Seniors Prescription Drug Relief Act of 2019
---S.2543: Prescription Drug Pricing Reduction Act of 2019
Medicaid
---Alternative Payment Arrangements for Gene Therapies
---Average Manufacturer Price Calculations
---Drug Benefit Design
---Pricing and Rebates
---S.2543: Prescription Drug Pricing Reduction Act of 2019
---S.3013: Encouraging Innovative Benefit Design to Lower Costs for Seniors Act
Reimbursement and Coverage of Innovative Products
---Administration Rebate Rule
---CMMI Authority
---H.R.488/S.99: Medicare Drug Price Negotiation Act of 2019
---International Pricing Index Proposal
---Medicare Part B Physician-Administered Products
---Medicare Part D Prescription Drug Program
---S.2543: Prescription Drug Pricing Reduction Act of 2019
---Step Therapy
---Value-based Contracting and Communications
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), White House Office, Council of Economic Advisers (CEA)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Jeanne |
Haggerty |
|
|
|
Michael |
Mattoon |
|
|
|
Thomas |
Brunet |
|
|
|
Shea |
Hartley |
|
|
|
Claire |
Brandewie |
|
|
|
Aiken |
Hackett |
|
|
|
Jamie |
Gregorian |
|
|
|
Charles |
Fritts |
|
|
|
David |
Lachmann |
|
|
|
Hayley |
Alexander |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code SMB
16. Specific lobbying issues
Capital Market Enhancements
---Accredited Investor Definition
---Amended Definition of Smaller Reporting Company
---Encouraging Employee Ownership Act
---SEC Rule 701
---SEC Small Business Forum
---Small Business Capital Formation Enhancement Act
Proxy Advisory Services
---Corporate Governance Reform and Transparency
---Impact of Policies on Small Public Companies
Sarbanes Oxley Section 404 (b)
---Reintroduction of the Fostering Innovation Act in the House of Representatives
---S.452: Fostering Innovation Act of 2019
---Small Issuer Exemption
Short Selling Transparency
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Securities & Exchange Commission (SEC)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
David |
Lachmann |
|
|
|
Jeanne |
Haggerty |
|
|
|
Cameron |
Arterton |
|
|
|
Michael |
Mattoon |
|
|
|
Shea |
Hartley |
|
|
|
John |
Guy |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
Antibiotic & Diagnostic Tax Credit
Biofuels (Non-Funding)
---Advanced and Second Generation Biofuels Tax Extenders
---H.R.3249/S.1841: Financing Our Energy Future Act of 2019
---H.R.3301: The Taxpayer Certainty and Disaster Tax Relief Act of 2019
Capital Formation Investment Incentives
---Introduction of the American Innovation Act in the Senate
---Reform of Net Operating Loss Rules
---Reintroduction of the American Innovation Act in the House
Orphan Drug Issues
---Tax Credit
Renewable Chemicals/Bio-based Products (Non-Funding)
---H.R.3249/S.1841: Financing Our Energy Future Act of 2019
---Investment Tax Credit
---Production Tax Credit
Research & Development Tax Credit Reforms
---Expensing of R&D Expenditures
---R&D Payroll Credit
Vaccine Injury Compensation Tax
---H.R.1973/S.1654: Vaccine Access Improvement Act of 2019
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Charles |
Fritts |
|
|
|
Erick |
Lutt |
|
|
|
Jeanne |
Haggerty |
|
|
|
Cameron |
Arteron |
|
|
|
Michael |
Mattoon |
|
|
|
Aiken |
Hackett |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TRD
16. Specific lobbying issues
Committee on Foreign Investment in the United States (CFIUS)
---Foreign Investment Risk Review Modernization Act (FIRRMA) Implementation
Drug Importation
---General
---H.R.1046/S.377: Medicare Negotiation and Competitive Licensing Act of 2019
---H.R.3164/S.2522: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2020
---S.97: Affordable and Safe Prescription Drug Importation Act of 2019
---S.771: Improving Access to Affordable Prescription Drugs Act of 2019
---S.844: Short on Competition Act of 2019
Foreign Agricultural Biotechnology Laws and Regulations
---Asynchronous Approvals
---China Biotechnology Regulations
---International Consistency of Regulation for Gene Edited Products
---Korea Biotechnology Regulations
Intellectual Property International Enforcement
---China
---Colombia
---India
---Malaysia
---Saudi Arabia
The United States-Mexico-Canada Agreement
---Ag-Biotech Provisions
---IP Provisions
US-China Trade Negotiations
---Ag Biotech Provisions
---IP Provisions
US-Japan Trade Agreement
---IP Provisions
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, U.S. Trade Representative (USTR), Treasury - Dept of, Agriculture - Dept of (USDA), Patent & Trademark Office (PTO)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Charles |
Fritts |
|
|
|
David |
Lachmann |
|
|
|
Jeanne |
Haggerty |
|
|
|
Matthew |
OMara |
|
|
|
Kyle |
Kunkler |
|
|
|
Shea |
Hartley |
|
|
|
Michael |
Mattoon |
|
|
|
Thomas |
Brunet |
|
|
|
Andrew |
Connor |
|
|
|
Cameron |
Arterton |
|
|
|
Aiken |
Hackett |
|
|
|
Jamie |
Gregorian |
|
|
|
Hayley |
Alexander |
|
|
|
Claire |
Brandewie |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code SCI
16. Specific lobbying issues
Engineering Biology
---H.R.4373: Engineering Biology Research and Development Act
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Kyle |
Kunkler |
|
|
|
Erick |
Lutt |
|
|
|
Michael |
Mattoon |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
| Address |
|
||||||
| City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
| City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
| 1 |
|
3 |
|
||||||
| 2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
| Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
||||||||||||||
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
| 1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
| Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% | |||||||||||||
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
| 1 | 3 | 5 |
| 2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
| Lobbyist Name | Description of Offense(s) |